Business
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.","length":522,"tagName":"p"},{"type":"image","alt":"Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Scott Liu (left), Founder, Chairman, and CEO of HanchorBio, signed the partnership agreement","displaySize":"","headline":null,"caption":"Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Scott Liu (left), Founder, Chairman, and CEO of HanchorBio, signed the partnership agreement","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/b49418b47fe5cb505941a8959e50389f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aKHSvXnYBlkWf3Ul2TPIHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b49418b47fe5cb505941a8959e50389f","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2869169/Dr_Chris_Chen__right__CEO_WuXi_Biologics_Dr_Scott_Liu.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.","length":531,"tagName":"p"},{"type":"text","content":"This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics' proven capabilities in c...